Related Experiment Video
Updated: May 24, 2025
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
6.0K
Haemophilia.
Pratima Chowdary1, Manuel Carcao2, Gili Kenet3
1Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK; Department of Haematology, Cancer Institute, University College London, London, UK.
Lancet (London, England)
|March 1, 2025
Summary
Haemophilia A and B are inherited bleeding disorders. Modern treatments, including factor replacement, non-replacement therapies, and gene therapy, significantly improve patient quality of life and reduce complications.
Area of Science:
- Hematology
- Genetics
- Pharmacology
Background:
- Congenital X-linked bleeding disorders caused by deficiencies in clotting factors VIII (haemophilia A) and IX (haemophilia B).
- Severe deficiency (<1% factor activity) leads to spontaneous bleeding in early childhood; moderate/mild forms present with bleeding after trauma or surgery.
- Early diagnosis through high index of suspicion and factor activity measurement is crucial.
Purpose of the Study:
- To review current and emerging management strategies for haemophilia A and B.
- To highlight the impact of therapeutic advances on patient outcomes.
- To emphasize the importance of personalized, lifelong care.
Main Methods:
- Review of current literature on haemophilia management.
- Analysis of different treatment modalities: factor replacement, non-replacement therapies, and gene therapy.
- Discussion of monitoring strategies for prophylactic treatments.
Main Results:
- Therapeutic advances have significantly improved mortality and morbidity in haemophilia.
- Various treatment options offer different benefits regarding prophylaxis, on-demand treatment, administration, and side-effect profiles.
- Personalized management, multidisciplinary teams, and patient education are key to optimal outcomes.
Conclusions:
- Comprehensive care and evolving treatment options enhance quality of life for individuals with haemophilia.
- Personalized, lifelong management strategies are essential for maximizing patient potential and minimizing disease burden.
- Continued research and education are vital for advancing haemophilia care.
Related Concept Videos
01:24Disorders of Hemostasis
676
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
676
01:19X-linked Traits
53.0K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
53.0K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
590
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
590
01:05Introduction to Hemostasis
4.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
4.9K
01:19Rh Blood Group
1.3K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.3K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
4.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.7K